The effect of cyclooxygenase-2 (COX-2) inhibition on human prostate cancer induced osteoblastic and osteolytic lesions in bone

Anticancer Research

Volumn 25, Issue 1 A, 2005, Pages 107-115

  Gamradt, Seth C ^a   Feeley, Brian T ^a   Liu, Nancy Q ^a   Roostaeian, Jason ^a   Lin, Ying Q ^a   Zhu, Li X ^a   Sharma, Sherven ^a   Dubinett, Steven M ^a   Lieberman, Jay R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bone metastases; COX 2; Osteoblastic; Osteolytic lessions; Prostate cancer

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; PROSTAGLANDIN E2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE DEVELOPMENT; BONE METASTASIS; BONE RADIOGRAPHY; CANCER GROWTH; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; KNOCKOUT MOUSE; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; SCID MOUSE; TIBIA; TISSUE HOMOGENATE; WESTERN BLOTTING;

ANIMALS; BONE NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; HUMANS; MALE; MEMBRANE PROTEINS; MICE; MICE, SCID; OSTEOBLASTS; OSTEOLYSIS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTATIC NEOPLASMS; PYRAZOLES; SULFONAMIDES;

EID: 16344393518     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Koeneman KS, Yeung F and Chung LW: Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 39: 246-261, 1999.
2. Koutsilieris M: Osteoblastic metastasis in advanced prostate cancer. Anticancer Res 13: 443-449, 1993.
3. Lange PH and Vessella RL: Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. Cancer Metastasis Rev 17: 331-336, 1998.
4. Goltzman D: Mechanisms of the development of osteoblastic metastases. Cancer 80: 1581-1587, 1997.
5. Mundy GR: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2: 584-593, 2002.
6. Keller ET, Zhang J, Cooper CR, Smith PC, McCauley LK, Pienta KJ and Taichman RS: Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metastasis Rev 20: 333-349, 2001.
7. Choong PF and Nadesapillai AP: Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. Clin Orthop S46-58, 2003.
8. Guise TA, Yin JJ and Mohammad KS: Role of endothelin-1 in osteoblastic bone metastases. Cancer 97: 779-784, 2003.
9. Koki A, Khan NK, Woerner BM, Dannenberg AJ, Olson L, Seibert K, Edwards D, Hardy M, Isakson P and Masferrer JL: Cyclooxygenase-2 in human pathological disease. Adv Exp Med Biol 507: 177-184, 2002.
10. Herschman HR: Primary response genes induced by growth factors and tumor promoters. Annu Rev Biochem 60: 281-319, 1991.
11. Dubinett SM, Sharma S, Huang M, Dohadwala M, Pold M and Mao JT: Cyclooxygenase-2 in lung cancer. Prog Exp Tumor Res 37: 138-162, 2003.
12. Dannenberg AJ and Howe LR: The role of COX-2 in breast and cervical cancer. Prog Exp Tumor Res 37: 90-106, 2003.
13. Church RD, Fleshman JW and McLeod HL: Cyclo-oxygenase 2 inhibition in colorectal cancer therapy. Br J Surg 90: 1055-1067, 2003.
14. Brecher AR: The role of cyclooxygenase-2 in the pathogenesis of skin cancer. J Drugs Dermatol 1: 44-47, 2002.
15. Pruthi RS, Derksen E and Gaston K: Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: a review. J Urol 169: 2352-2359, 2003.
16. Sabichi AL and Lippman SM: COX-2 inhibitors and other NSAIDs in bladder and prostate cancer. Prog Exp Tumor Res 37: 163-178, 2003.
17. Dannenberg AJ and Subbaramaiah K: Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 4: 431-436, 2003.
18. Wadhwa S, Godwin SL, Peterson DR, Epstein MA, Raisz LG and Pilbeam CC: Fluid flow induction of cyclo-oxygenase 2 gene expression in osteoblasts is dependent on an extracellular signal-regulated kinase signaling pathway. J Bone Miner Res 17: 266-274, 2002.
19. Zhang X, Schwarz EM, Young DA, Puzas JE, Rosier RN and O'Keefe RJ: Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 109: 1405-1415, 2002.
20. Forwood MR: Inducible cyclo-oxygenase (COX-2) mediates the induction of bone formation by mechanical loading in vivo. J Bone Miner Res 11: 1688-1693, 1996.
21. Reich KM and Frangos JA: Effect of flow on prostaglandin E2 and inositol trisphosphate levels in osteoblasts. Am J Physiol 261: C428-432, 1991.
22. Simon AM, Manigrasso MB and O'Connor JP: Cyclo-oxygenase 2 function is essential for bone fracture healing. J Bone Miner Res 17: 963-976, 2002.
23. Kawaguchi H, Pilbeam CC, Harrison JR and Raisz LG: The role of prostaglandins in the regulation of bone metabolism. Clin Orthop 36-46, 1995.
24. Weinreb M, Suponitzky I and Keila S: Systemic administration of an anabolic dose of PGE2 in young rats increases the osteogenic capacity of bone marrow. Bone 20: 521-526, 1997.
25. Suponitzky I and Weinreb M: Differential effects of systemic prostaglandin E2 on bone mass in rat long bones and calvariae. J Endocrinol 156: 51-57, 1998.
26. Tsingotjidou AS, Zotalis G, Jackson KR, Sawyers C, Puzas JE, Hicks DG, Reiter R and Lieberman JR: Development of an animal model for prostate cancer cell metastasis to adult human bone. Anticancer Res 21: 971-978, 2001.
27. Lee YP, Schwarz EM, Davies M, Jo M, Gates J, Zhang X, Wu J and Lieberman JR: Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model. Cancer Res 62: 5564-5570, 2002.
28. Lee Y, Schwarz E, Davies M, Jo M, Gates J, Wu J, Zhang X and Lieberman JR: Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone. J Orthop Res 21: 62-72, 2003.
29. Whang PGI, R C; Lieberman, J R The soluble receptor activator of NF-KB: FC fusion protein inhibits osteolytic and osteoblastic lesions induced by human prostate cancer cells. In: Proceedings of the Orthopaedic Research Society, New Orleans, LA, 2003.
30. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF and Jones LW: Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17: 16-23, 1979.
31. Craft N, Chhor C, Tran C, Belldegrun A, DeKernion J, Witte ON, Said J, Reiter RE and Sawyers CL: Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res 59: 5030-5036, 1999.
32. Wu TT, Sikes RA, Cui Q, Thalmann GN, Kao C, Murphy CF, Yang H, Zhau HE, Balian G and Chung LW: Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. Int J Cancer 77: 887-894, 1998.
33. Kiertscher SM, Luo J, Dubinett SM and Roth MD: Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol 164: 1269-1276, 2000.
34. Huang M, Stolina M, Sharma S, Mao JT, Zhu L, Miller PW, Wollman J, Herschman H and Dubinett SM: Non-small cell lung cancer cyclooxygenase-2- dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 58: 1208-1216, 1998.
35. Stolina M, Sharma S, Lin Y, Dohadwala M, Gardner B, Luo J, Zhu L, Kronenberg M, Miller PW, Portanova J, Lee JC and Dubinett SM: Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 164: 361-370, 2000.
36. Choong PF: The molecular basis of skeletal metastases. Clin Orthop S19-31, 2003.
37. Kirschenbaum A, Liu X, Yao S and Levine AC: The role of cyclooxygenase-2 in prostate cancer. Urology 58: 127-131, 2001.
38. Autzen P, Robson CN, Bjartell A, Malcolm AJ, Johnson MI, Neal DE and Hamdy FC: Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. Br J Cancer 78: 1219-1223, 1998.
39. Harris SE, Harris MA, Mahy P, Wozney J, Feng JQ and Mundy GR: Expression of bone morphogenetic protein messenger RNAs by normal rat and human prostate and prostate cancer cells. Prostate 24: 204-211, 1994.
40. Yin JJ, Mohammad KS, Kakonen SM, Harris S, Wu-Wong JR, Wessale JL, Padley RJ, Garrett IR, Chirgwin JM and Guise TA: A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA 100: 10954-10959, 2003.
41. Mohammad KS and Guise TA: Mechanisms of osteoblastic metastases: role of endothelin-1. Clin Orthop S67-74, 2003.
42. Chiao JW, Moonga BS, Yang YM, Kancherla R, Mittelman A, Wu-Wong JR and Ahmed T: Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. Br J Cancer 83: 360-365, 2000.
43. Fizazi K, Yang J, Peleg S, Sikes CR, Kreimann EL, Daliani D, Olive M, Raymond KA, Janus TJ, Logothetis CJ, Karsenty G and Navone NM: Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res 9: 2587-2597, 2003.
44. Rabbani SA, Mazar AP, Bernier SM, Haq M, Bolivar I, Henkin J and Goltzman D: Structural requirements for the growth factor activity of the amino-terminal domain of urokinase. J Biol Chem 267: 14151-14156, 1992.
45. Achbarou A, Kaiser S, Tremblay G, Ste-Marie LG, Brodt P, Goltzman D and Rabbani SA: Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 54: 2372-2377, 1994.
46. Marquardt H, Lioubin MN and Ikeda T: Complete amino acid sequence of human transforming growth factor type beta 2. J Biol Chem 262: 12127-12131, 1987.
47. Nelson JB, Nguyen SH, Wu-Wong JR, Opgenorth TJ, Dixon DB, Chung LW and Inoue N: New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology 55: 1063-1069, 1999.
48. Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA and Simons JW: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1: 944-949, 1995.
49. Chirgwin JM and Guise TA: Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr 10: 159-178, 2000.
50. Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J and Keller ET: Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 107: 1235-1244, 2001.
51. Zhang J, Dai J, Yao Z, Lu Y, Dougall W and Keller ET: Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. Cancer Res 63: 7883-7890, 2003.
52. Ono K, Akatsu T, Murakami T, Kitamura R, Yamamoto M, Shinomiya N, Rokutanda M, Sasaki T, Amizuka N, Ozawa H, Nagata N and Kugai N: Involvement of cyclo-oxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines. J Bone Miner Res 17: 774-781, 2002.
53. Ono K, Akatsu T, Kugai N, Pilbeam CC and Raisz LG: The effect of deletion of cyclooxygenase-2, prostaglandin receptor EP2, or EP4 in bone marrow cells on osteoclasts induced by mouse mammary cancer cell lines. Bone 33: 798-804, 2003.
54. Ohshiba T, Miyaura C and Ito A: Role of prostaglandin E produced by osteoblasts in osteolysis due to bone metastasis. Biochem Biophys Res Commun 300: 957-964, 2003.